

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to: Office of Initial Patent Examination's Filing Receipt Corrections, (Group Art Unit 1641) at (703) 746-9195 of the U.S. Patent and Trademark Office on May 28, 2004.
TOTAL PAGES 6.

C. Fong
C. FONG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Petitions Attorney: Douglas I. Wood
Avi J. ASHKENAZI, et al..)	Art Unit: 1641
Application Serial No. 10/633,008)	Attorney's Docket No. 39766-0100 P1
Filed: July 31, 2003)	Customer No. 25213
For: USE OF A33 ANTIGENS AND JAM-IT)	

REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Attached is a copy of the official filing receipt received from the U.S. Patent and Trademark Office in the above application for which issuance of a corrected filing receipt is respectfully requested. The title of this application is incorrectly entered.

The correct title, as evidenced by the attached copy of the first page of the application as filed, the post card stamped and returned by the PTO and the application transmittal is:

USE OF A33 ANTIGENS AND JAM-IT.

Applicants submit that because the correction is not due to any error by applicants, no fee is due. However, in the event that a fee is due, the Commissioner is hereby authorized to charge any such fees to Deposit Account No. 08-1641 (Attorney Docket No. 39766-0100 P1).

Respectfully submitted,

Dated: May 28, 2004

By: *Ginger R. Dreger*
Ginger R. Dreger (Reg. No. 33,055)

HELLER EHRMAN WHITE & McAULIFFE LLP
275 Middlefield Road
Menlo Park, California 94025
Telephone: (650) 324-7184
Facsimile: (650) 324-6638

SRM



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/633,008	07/31/2003	1641	1642	39766-0100P1	75	39	8

Ginger R. Dreger, Esq.
 HELLER EHRMAN WHITE & MCAULIFFE, LLP
 275 Middlefield Road
 Menlo Park, CA 94025

RECEIVED
MAR 22 2004
 HELLER EHRMAN

CONFIRMATION NO. 8996
 UPDATED FILING RECEIPT

OC000000012118670

Date Mailed: 03/17/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Avi Ashkenazi, San Mateo, CA;
 Sherman Fong, Alameda, CA;
 Audrey Goddard, San Francisco, CA;
 Austin L. Gurney, Belmont, CA;
 Mary A. Napier, Hillsborough, CA;
 Daniel Tumas, Orinda, CA;
 Menno Van Lookeren, San Francisco, CA;
 William I. Wood, Hillsborough, CA;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/265,542 10/03/2002
 which is a CIP of PCT/US00/04414 02/22/2000
 and is a CIP of PCT/US00/14042 05/22/2000
 and is a CIP of PCT/US00/32678 12/01/2000
 and is a CIP of 09/254,465 03/05/1999 PAT 6,410,708
 and is a CIP of PCT/US99/05028 03/08/1999
 and is a CIP of 09/380,138 08/25/1999 ABN
 and is a CIP of 09/380,139 08/25/1999 ABN
 and is a CIP of PCT/US98/19330 09/16/1998
 and is a CIP of 09/953,499 09/14/2001
 which is a CON of PCT/US98/24855 11/20/1998

Foreign Applications

If Required, Foreign Filing License Granted: 10/20/2003

DOCKETED

Projected Publication Date: 06/24/2004

Non-Publication Request: No

Early Publication Request: No

Title

AND
Use of A33 antigens/JAM-it

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Please type a plus sign (+) inside this box ☐

PTO/SB/05 (08/00)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	39766-0100P1
	First Inventor or Application Identifier	Ashkenazi, et al.
	Title	USE OF A33 ANTIGENS AND JAM-IT
	Express Mail Label No.	EV346725843US

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>	ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i> 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. 3. <input checked="" type="checkbox"/> Specification <i>[Total Pages 129]</i> <i>(preferred arrangement set forth below)</i> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed-Sponsored R&D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Detailed Description of the Drawings - Detailed Description - Claim(s) 4. <input checked="" type="checkbox"/> Drawing(s) (37CFR 1.152) (informal) <i>[Total Sheets 75]</i> 5. <input checked="" type="checkbox"/> Oath or Declaration <i>[Total Pages 1]</i> a. <input checked="" type="checkbox"/> Un executed b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	7. <input checked="" type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i> 8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i> 11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 12. <input type="checkbox"/> Information Disclosure Statement (IDS) PTO-1449 <input type="checkbox"/> Copies of IDS Citations 13. <input type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 16. <input checked="" type="checkbox"/> Other: <u>Copy of Petition to Accept Application under 37 CFR 1.47(a); copy of Statement of Facts in Support of 37 CFR 1.47(a) Petition; and copy of USPTO decision regarding Petition under CFR 1.47(a)</u>

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No. 10/265,542, filed 10/03/02Prior application information: Examiner Unassigned

Group/Art Unit: 1774

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label 25213 or ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME	Ginger R. Dreger, Esq.				
ADDRESS	HELLER EHRMAN WHITE & MCAULIFFE, LLP				
	275 Middlefield Road				
CITY	Menlo Park	STATE	California	ZIP CODE	94025
COUNTRY	USA	TELEPHONE	650/324-7000	FAX	650/324-0638

Name (Print/Type)	Ginger R. Dreger, Esq.	Registration No. (Attorney/Agent)	33,055
Signature		Date	July 31, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

GRD/
ALB

THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACKNOWLEDGMENT AND RECEIPT FOR FILING

03913 U.S. PTO

10/633008



07/31/03

Applicant: Ashkenazi, et al. Serial No. Unassigned
Filing Date: July 31, 2003 Examiner Unassigned
Title: USE OF A33 ANTIGENS AND JAM-IT

- ☒ Transmittal;
- ☒ Fee Transmittal;
- ☒ 129 page specification, claims and abstract;
- ☒ Unexecuted DEC/POA;
- ☒ 75 sheets of informal drawings;
- ☒ Statement under 37 CFR 1.821(f) and (g);
- ☒ Sequence Listing with CRF diskette (17 pages);
- ☒ Copy of Petition to Accept Application under 37 CFR 1.47(a);
- ☒ Copy of Statement of Facts in Support of 37 CFR 1.47(a) Petition;
- ☒ Copy of USPTO correspondence granting 37 CFR 1.47(a) petition; and
- ☒ Check No. 125383 in the amount of \$1,512.00 for application filing fees.

Attorney Docket No.: 39766-0100P1

Date: July 31, 2003

GRD/car VIA EXPRESS MAIL NO. EV346725843US

RECEIVED BY THE UNITED STATES PATENT OFFICE

DOCKETED

39766-0100P1

PATENT

USE OF A33 ANTIGENS AND JAM-IT

[0001] The present application is a continuation in part of copending application Serial No. 10,265,542 filed October 3, 2002, which is a continuation in part of PCT international application no. PCT/US00/04414, filed February 22, 2000, as a continuation in part of PCT international application no. PCT/US00/14042, filed May 22, 2000, as a continuation in part of PCT international application no. PCT/US00/32678, filed December 1, 2000, as a continuation in part of U.S. application no. 09/254,465, filed March 5, 1999, now, U.S. Patent No. 6,410,708, as a continuation in part of PCT international application no. PCT/US99/05028, filed March 8, 1999, as a continuation in part of U.S. application no. 09/380,138, filed August 25, 1999, as a continuation in part of U.S. application no. 09/380,139, filed August 25, 1999, now abandoned, as a continuation in part of PCT international application no. PCT/US98/19330, filed September 16, 1998, and as a continuation in part of U.S. application no. 09/953,499, filed September 14, 2001, which in turn is a continuation application, claiming priority under 35 U.S.C. §120 as a continuation of PCT international application no. PCT/US98/24855, filed November 20, 1998.

Background of the InventionField of the Invention

[0002] The present invention relates generally to the identification, isolation and recombinant production of novel DNA and novel polypeptides the presence of which is associated with inflammatory diseases (inflammation associated antigens) and/or cancer, and to compositions and methods for the diagnosis and treatment of conditions characterized by such antigens.

Description of the Related Art

[0003] The inflammatory response is complex and is mediated by a variety of signaling molecules produced locally by mast cells, nerve endings, platelets, leukocytes and complement activation. Certain of these signaling molecules cause the endothelial cell lining to become more porous and/or even to express selections which act as cell surface molecules which recognize and attract leukocytes through specific carbohydrate recognition. Stronger leukocyte binding is mediated by integrins, which mediate leukocyte movement through the endothelium. Additional signaling molecules act as chemoattractants, causing the bound leukocytes to crawl towards the source of the attractant. Other signaling molecules produced in the course of an inflammatory